Presenter: Judkins, Zachary

Seminar Date: 2013-10-30

Presenter Scores

,					Faculty Survey Data Averages								nal Scores				
	Inst. Materials	Overall Pres.	Clinical Data	Conc.	Q&A	Overall Knowledge	Pres. Style	Inst. Materials	Overall Pres.	Clinical Data	Conc.	Q&A	Overall Know.	Prep.	Prof.	Att.	Total
6.66	6.68	6.86	6.79	6.8	6.58		6.38			6.17	6.38	5.75	6	0	0	0	E (46.13)

Р	Presentation Style										
#	Question	Α	A-	B+	В	B-	C+	С	Mean		
1	Moderate Pace	1	1	0	0	0	0	0	6.5		
2	Thorough eye contact/ minimal reliance on notes	1	1	0	0	0	0	0	6.5		
3	Displayed professionalism/ poise/ confidence/ lacked distracting mannerisms	0	1	1	0	0	0	0	5.5		
4	Material presented at the appropriate level for the audience	2	0	0	0	0	0	0	7		

Presentation Style Comments

Keep working on eye contact, position body in way that can comfortably see all the audience and slides - without having to glance behind you to see the slides. // You are quite soft spoken, I would encourage you to use microphone in the future. // Clearing throat during presentation - not sure if this was nerves but have water with you and make sure comfortable before starting:)

Your volume as a little low so sometimes it was kind of hard to hear you. I did appreciate your jokes - especially the 1 person and 2 arms, and your denial animation. You seemed to have a little trouble with the controller you used to advance the slides and so sometimes this was a bit distracting as you seemed to be making a point but then the slides went forward to the next topic.

Ir	Instructional Materials											
#	Question	Α	A-	B+	В	B-	C+	С	NA	Mean		
1	Slides and handout were clear/easy to read	0	0	2	0	0	0	0	0	5		
2	Slides and handout are devoid of spelling and grammatical errors	1	1	0	0	0	0	0	0	6.5		
3	Provided orientation to charts/graphs/pictures/diagrams (if applicable)	0	2	0	0	0	0	0	0	6		
4	Cites appropriate references/correct referencing style and emphasizes primary literature	0	1	1	0	0	0	0	0	5.5		

Instructional Materials Comments

Font size on slides was often small - increase font size, minimize words on slides as much as possible.

Most of the slides were easy to follow, some of the writing was a bit small when reading from the rear of the room. I appreciated that you showed at least one "data slide" but it would have been helpful to orient the audience to the graph first. Finally, while you did reference the studies, it is appropriate to be very overt with a minimum of the lead author and year (or study name if it is well known) when identifying a study on your slides.

0	Overall Presentation Content											
#	Question	Α	A-	B+	В	B-	C+	С	Mean			
1	Introduction, interest in topic, and outline/objectives described	1	1	0	0	0	0	0	6.5			
2	Defines purpose/controversy of seminar topic clearly	0	2	0	0	0	0	0	6			
3	Objectives clear and useful for self assessment	1	1	0	0	0	0	0	6.5			
4	Appropriate background information was provided	1	0	1	0	0	0	0	6			
5	Well organized presentations and smooth transitions (appropriate 'flow')	1	1	0	0	0	0	0	6.5			

Overall Presentation Content Comments

Good presentation of interest in topic and review of other agents used for adjunct depression. Might have liked some comparision or discussion of generally expected benefit of other adjunct therapy (ie. 30% of patients given bupropion adjunct respond) to give us some context for evaluating modafinil. Context with major landmark trials like STARD would also help with evaluating: length of trial, number of patients enrolled, etc.

You did a very good job of providing the background on the modafinil and suggesting alternatives for patient care and discussing the weaknesses of the studies available for this agent.

Presentation of Clinical Data										
#	Question	Α	A-	B+	В	B-	C+	С	NA	Mean
1	Presented concise objectives, methodology and treatment for each study	1	1	0	0	0	0	0	0	6.5
2	Outcome measures were stated and described, and appropriateness was explained	0	2	0	0	0	0	0	0	6
3	Presented key trial results with corresponding statistical analysis	1	1	0	0	0	0	0	0	6.5
4	Student is able to determine if sample size and power is appropriate (if applicable)	0	2	0	0	0	0	0	0	6
5	Withdrawals and dropouts are accounted for (if applicable)	0	2	0	0	0	0	0	0	6
6	Provided a detailed & thoughtful analysis of study strengths and limitations	1	0	1	0	0	0	0	0	6

Presentation of Clinical Data Comments

Important to analyze study in context of other landmark trials for depression, being familiar with these would help.

I thought that you did a good job of presenting a thoughtful analysis of the results and keeping key questions at the forefront. You also did a good job of relating the numerical findings to their clinical meaning.

С	Conclusions											
#	Question	Α	A-	B+	В	B-	C+	С	Mean			
1	Conclusions are supported by data presented in the seminar	1	1	0	0	0	0	0	6.5			
2	Clinical importance and application of the study is discussed	1	1	0	0	0	0	0	6.5			
3	Provided specific recommendations for clinical pharmacy practice	0	2	0	0	0	0	0	6			
4	Discussed the role of the pharmacist and/or impact to the profession of pharmacy in regards to the use of the treatment	1	1	0	0	0	0	0	6.5			

Conclusions Comments

Liked discussion (when prompted) about how request for managed care perspective would be addressed. Would have also liked your clinical recommendation - ie. when a provider or patient asks you if you would recommend this treatment.

Based on the studies you discussed, the rationale for limiting the use of modafinil for MDD seemed very appropriate. It is unfortunate that better studies are not available - it makes one wonder if it was just a flaw in design or are there reasons that may not have been clearly articulated why the study was performed the way it was?

Q	Question Answer Session									
#	Question	Α	A-	B+	В	B-	C+	С	Mean	
1	Succinctly, yet thoroughly answered audience questions	0	1	1	0	0	0	0	5.5	
2	Encouraged questions and interaction with the audience	0	2	0	0	0	0	0	6	

Question Answer Session Comments

Many of the questions asked pointed our definiciencies in presentation - information that probably should have been included. Good job answering these on the spot and keeping your cool!

I think that you had thought about study design so it was a bit surprising that, when challenged, you "walked back on your recommendation". Nevertheless, I think it is better that you could reassess your position rather than "stand by" your original position when you feel that there may be a logical error in that original position.

Overall Knowledge Base										
#	Question	Α	A-	B+	В	B-	C+	С	Mean	
1	Demonstrated knowledge of subject beyond the facts presented in the seminar	1	0	1	0	0	0	0	6	
2	Student is able to distinguish the difference between clinical and statistical significance	1	1	0	0	0	0	0	6.5	
3	Student is able to look beyond the author's conclusions and offer insight into the overall study results	1	1	0	0	0	0	0	6.5	
4	Student is able to discuss conclusions in the context of previous research and in comparison to current practice/therapy	0	0	1	1	0	0	0	4.5	
5	Student is able to think on his/her feet. May theorize if not sure of answer, but identifies answer as such	1	1	0	0	0	0	0	6.5	

Overall Knowledge Base Comments

As discussed previously, would have liked more comparison in the context of current therapeutic options and clinical practice. Briefly discussed cost, covered efficacy well, would have liked more discussion of safety and tolerability - especially in context of studies reviewed. So much of treatment decisions for depression are based on AE and tolerability!

You clearly had a good grasp of MDD therapeutics. If the STAR*D trial is the benchmark trial, it is appropriate to compare the design and analysis of the trials you found to this benchmark.

Overall Comments

Overall good job, I think you have made good progress in your presentation style since last year and seemed noticably more comfortable this year speaking in front of the group:) Remember, that you need to be the expert on a subject and that knowing the context for the data you are presenting is very important!

Overall, you did a good job on what seemed to be a tough subject since the trials had considerable weaknesses associated with them. Nevertheless, you were able to take the information and suggest a clinically relevant position to think about modafinil in the overall treatment of MDD.